by Richard Daverman, PhD
February 13, 2013 -- Celgene Corporation was granted approval for Revlimid ® (lenalidomide) by the SFDA for Revlimid ® (lenalidomide) to treat multiple myeloma. The approval, which is the first for Celgene in China, includes an Import Drug License. Revlimid is indicated for use in combination with dexamethasone in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. In 2006, the drug was approved for a similar indication in the US. More details....
Stock Symbol: (NSDQ: CELG)
